Sjouke Vandenberghe, PhD

Janssen Infectious Diseases
Beerse, Antwerpen, Belgium

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 2321 - Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level

  Saturday, October 22, 2022
  2:30 PM – 2:45 PM US ET